What Is The Current and Historic Market Size Analysis Of The Ankylosing Spondylitis Market?
The ankylosing spondylitis market has seen considerable growth due to a variety of factors.
•In recent years, there has been a significant increase in the market size of ankylosing spondylitis. It is projected to expand from $5.9 billion in 2024 to $6.36 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%.
Several factors contributed to this growth over the past years, including the discovery of hla-b27, the development of biologic treatments, approaches to pain management, advocacy and awareness initiatives for patients, as well as NSAIDs and the use of disease modifying drugs.
What Are The Predictions for The Ankylosing Spondylitis Market Size In The Coming Years?
The ankylosing spondylitis market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for ankylosing spondylitis is predicted to surge considerably in the forthcoming years. By 2029, the market is anticipated to balloon to $8.71 billion, with a compound annual growth rate (CAGR) of 8.2%.
The predicted growth during this period can be credited to factors such as customized healthcare strategies, the development of unique biologics, early intervention and screening initiatives, lifestyle and diet regulation, as well as telemedicine and remote monitoring. Significant patterns forecasted for this period involve the accessibility of biosimilars, targeted pain treatments, focus on patient-reported outcomes (pros), community support initiatives, and the examination of regenerative medicine.
Which Key Drivers Are Propelling The Ankylosing Spondylitis Market's Growth?
The surge in the elderly population is projected to stimulate the expansion of the ankylosing spondylitis market in the future. An increase in the aged population derives from a shift in age ratios within a society. This shift results in a rise in both the count and the percentage of individuals who are 60 or above. Therapies and medications for ankylosing spondylitis serve to enhance mobility and control pain among senior citizens who have this condition. Take, for instance, a prediction from the UN Department of Economic and Social Affairs (UN DESA), a department based in the US that operates under the UN Secretariat. According to the department's January 2023 forecast, the worldwide population of those who are 65 or older is predicted to more than double, jumping from 761 million in 2021 to 1.6 billion by 2050. Hence, the escalating older population is facilitating the expansion of the ankylosing spondylitis market.
What Are The Key Segments Within The Global Ankylosing Spondylitis Market?
The ankylosing spondylitis market covered in this report is segmented –
1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery
2) By Molecule: Biologics, Biosimilar, Small Molecules
3) By Route Of Administration: Parenteral, Oral, Other Routes
4) By Application: Juveniles, Adults
5) By End User: Hospitals, Clinics, Research Laboratories, Other End Users
Subsegments:
1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs
3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors
4) By Steroids: Oral Steroids, Injectable Steroids
5) By Physical Therapies: Physiotherapy, Exercise Programs
6) By Surgery: Joint Replacement Surgery, Spinal Surgery
Pre-Book The Ankylosing Spondylitis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Ankylosing Spondylitis Market?
The progression in therapeutic possibilities is a notable trend emerging in the ankylosing spondylitis market. To maintain their market standing, companies in the ankylosing spondylitis space are developing novel therapeutic solutions. Take for example, AbbVie Inc., a biopharmaceutical company based in the US, who in April 2022, publicised that RINVOQ had received the green light from the U.S. Food and Drug Administration (FDA) for use in treating adults with active ankylosing spondylitis (AS). This gives a fresh oral treatment option for patients whose response to TNF blockers has been inadequate, demonstrating appreciable betterment in disease signs such as back pain and physical function. The quick effectiveness and safety profile ascertained from clinical trials render it a substantial advancement in managing this chronic inflammatory condition, thereby broadening the range of therapeutic options accessible to patients.
Who Are the Key Players in the Ankylosing Spondylitis Market?
Major companies operating in the ankylosing spondylitis market include:
• Pfizer Inc.
• Johnson & Johnson Pvt. Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Bristol-Myers Squibb
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Cedars-Sinai
• Viatris Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• UCB Inc.
• Cipla Inc.
• Zydus Lifesciences Limited
• Celltrion Inc.
• Hetero Labs Ltd.
• UCSF Health
• Janssen Biotech Inc.
• Reliance Life Sciences Pvt. Ltd.
What are the Regional Insights into the Ankylosing Spondylitis Market?
North America was the largest region in the ankylosing spondylitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
